Pulmonary hypertension最新文献_第10页

Body mass index predicts survival in patients with pulmonary hypertension in chronic lung disease 体重指数预测慢性肺病肺动脉高压患者的生存

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1430

O. Nishiyama, Kazuya Yoshikawa, S. Saeki, Ryo Yamazaki, H. Sano, T. Iwanaga, Y. Tohda

引用次数: 0

Macitentan modulates pulmonary mRNA levels of gremlin 1 in a rat model of pulmonary arterial hypertension 马西坦调节肺动脉高压大鼠模型中格莱姆林1的mRNA水平

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1418

E. Schiavi, S. Cantoni, G. Volpi, M. Cont, F. Pastore, S. Cavalli, F. Dardi, G. Villetti, F. Facchinetti

引用次数: 0

Survival implications of pulmonary hypertension in end-stage COPD 肺动脉高压对终末期COPD患者生存的影响

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1426

A. Kapasi, K. Halloran, A. Hirji, D. Lien, J. Mooney, R. Raj, A. Sweatt, J. Weinkauf, R. Zamanian

{"title":"Survival implications of pulmonary hypertension in end-stage COPD","authors":"A. Kapasi, K. Halloran, A. Hirji, D. Lien, J. Mooney, R. Raj, A. Sweatt, J. Weinkauf, R. Zamanian","doi":"10.1183/13993003.congress-2019.pa1426","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa1426","url":null,"abstract":"Pulmonary hypertension (PH) is a common finding in chronic obstructive pulmonary disease (COPD) and is associated with poor outcomes. Our objective was to evaluate the survival implications of PH in end-stage COPD. Methods: We performed a retrospective review of adult COPD patients in the Scientific Registry of Transplant Recipients between Jan 2005 and Dec 2014. Patients were classified as:\u0000 PH absent (mean pulmonary artery pressure (mPAP) Borderline PH, preserved pulmonary vascular resistance (PVR) (mPAP 21-24 mmHg, PVR Borderline PH, high PVR (PVR ≥3 WU) PH, non-elevated PVR (mPAP 25-34 mmHg, PVR PH, high PVR (PVR ≥3 WU) Severe PH (mPAP ≥35 mmHg) Groups were evaluated by log rank test and Cox regression modeling. Patients were censored at transplant. Results: Of 4339 patients, 2287 (53%) had PH, 438 (10%) had severe PH, and 1229 died. Median survival was 4.5y (95% CI 4.1-5y) in group 1, and 2.8y (95% CI 2.5-3.6y) in group 6 (p Conclusions: COPD patients with borderline PH and PH had similarly increased risks of death (regardless of PVR), and those with severe PH had a further increase in risk. These findings are distinct from other lung diseases such as IPF, and suggest the need for a separate ontology for COPD-PH.","PeriodicalId":20724,"journal":{"name":"Pulmonary hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90497884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

6 minute walk work and other clinical correlates of peak VO2 in pulmonary vascular disease 肺血管疾病患者6分钟步行、工作和其他临床相关VO2峰值

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa5469

Lucy Robertson, K. Oates, A. Fletcher, K. Sylvester

{"title":"6 minute walk work and other clinical correlates of peak VO2 in pulmonary vascular disease","authors":"Lucy Robertson, K. Oates, A. Fletcher, K. Sylvester","doi":"10.1183/13993003.congress-2019.pa5469","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa5469","url":null,"abstract":"Background: Peak VO2 is the gold standard for assessing exercise capacity but 6 minute walk distance (6MWD) is mostly used surrogate measure. However, body mass may influence the predictive ability of 6MWD. Hence, 6 minute walk work (6MWW=6MWD X bodyweight) is an alternative measure but has not been fully investigated in all pulmonary vascular disease (PVD) groups. Aims: In PVD patients; 1) To determine whether 6MWW and/or other clinical parameters correlate with peak VO2. 2) Investigate the ability to predict peak VO2 from other measures, such as 6MWW. Method: Clinical data was retrospectively analysed from 38 chronic thromboembolic pulmonary hypertension (CTEPH),41 chronic thromboembolic disease (CTED), and 13 pulmonary hypertension (PH) patients. 6MWD, 6MWW, lung function, echocardiogram and right heart catheter (RHC) data were correlated with peak VO2. Results: A number of 6 minute walk measures, lung function, RHC and echocardiogram parameters correlated to peak VO2. Amongst the PVD groups 6MWW and TLCO were the highest correlated to peak VO2 (Table 1). Following linear regression analysis a predictive equation was produced in CTEPH and CTED groups. CTEPH=VO2 (ml/min) = - 252 + 0.049*6MWW (R2 = 0.79) CTED=VO2 (ml/min) = - 266 + 0.028*6MWW + 147.6*TLCO (adjusted R2 = 0.78). Conclusion: 6MWW is highly correlated to peak VO2 in PVD suggesting body mass does influence the predictive power of 6MWD. Further work is needed to validate the generated predicted equations.","PeriodicalId":20724,"journal":{"name":"Pulmonary hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82290932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MiR-1-5p targets TGF-ßR1 and is suppressed in the hypertrophying hearts of rats with pulmonary arterial hypertension MiR-1-5p靶向TGF-ßR1，在肺动脉高压大鼠肥厚心脏中受到抑制

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa5045

Martin Connolly, S. Wort, B. Garfield, A. Crosby, N. Morrell, P. Kemp

引用次数: 1

Pharmacological inhibition of carbonic anhydrases 9 and 12 attenuates monocrotaline-induced pulmonary hypertension in rats 碳酸酐酶9和12的药理学抑制可减轻单罂粟碱诱导的大鼠肺动脉高压

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1417

A. Petrović, D. Kosanovic, O. Pak, Jan Niklas Schneider, A. Sydykov, N. Weissmann, W. Seeger, R. Schermuly

引用次数: 0

Iron Deficiency in Chronic Thromboembolic Pulmonary Hypertension 慢性血栓栓塞性肺动脉高压缺铁

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa1443

I. Campean, R. Sadushi-Koliçi, H. Beckmann, I. Shafran, Nika Skoro Sajer, I. Lang

引用次数: 2

Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy 直接口服抗凝剂使用和血栓检测慢性血栓栓塞性肺动脉高压患者转介肺血栓动脉内膜切除术

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa5161

Ina Jeong, T. Fernandes, M. Alotaibi, N. Kim

{"title":"Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy","authors":"Ina Jeong, T. Fernandes, M. Alotaibi, N. Kim","doi":"10.1183/13993003.congress-2019.oa5161","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.oa5161","url":null,"abstract":"Background: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) should be on lifelong, effective anticoagulant therapy. The safety and efficacy of direct oral anticoagulant (DOAC) in CTEPH is unknown. Aim: To evaluate the trend of DOAC usage and correlation with subacute thrombus detection at time of pulmonary thromboendarterectomy. Methods: We performed a retrospective analysis of 405 consecutive pulmonary thromboendarterectomy (PTE) cases at the University of California, San Diego from July 2015 through July 2017. The PTE specimen were reviewed for the presence of acute or subacute thrombotic material removed at the time of PTE. Results: Of 405 consecutive PTE cases, 239 (59.0%) presented on either oral vitamin-K antagonist or chronic injectable therapy; 166 patients (41%) were anticoagulated with DOACs. There were no significant differences in baseline characteristics between DOAC and non-DOAC groups. Evidence of acute or subacute thrombi was observed in 16 (6.7%) within the non-DOAC group versus 22 (13.3%) in the DOAC group. The odds ratio (OR) of DOACs usage and evidence of recent thrombosis was 2.34 (95% CI, 1.09-5.01, p=0.028) after adjusting for age, gender, race, BMI, and history of antiphospholipid antibody syndrome. Conclusions: CTEPH patients referred for PTE while on DOAC therapy were twice as likely to have associated acute or subacute thrombi removed at the time of surgery compared with those on conventional anticoagulant therapies. This raises questions of safety and efficacy of DOACs in the chronic treatment of CTEPH. A formal study of DOACs in the management of CTEPH is indicated.","PeriodicalId":20724,"journal":{"name":"Pulmonary hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74215450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Late Breaking Abstract - Validation of the REVEAL 2.0 Risk Score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort 摘要:REVEAL 2.0风险评分在澳大利亚和新西兰肺动脉高压登记队列中的验证

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.oa495

James J. Anderson, E. Lau, M. Lavender, R. Benza, D. Celermajer, N. Collins, C. Corrigan, N. Dwyer, J. Feenstra, M. Horrigan, D. Keating, E. Kotlyar, T. McWilliams, Bronwen Rhodes, P. Steele, V. Thakkar, T. Williams, H. Whitford, K. Whyte, R. Weintraub, J. Wrobel, A. Keogh, G. Strange

引用次数: 0

Evolution of patients with Pulmonary Arterial Hypertension (PAH) six months after an exercise training program 运动训练计划后6个月肺动脉高压(PAH)患者的演变

Pulmonary hypertension Pub Date : 2019-09-28 DOI: 10.1183/13993003.congress-2019.pa4753

Clara Martin Ontiyuelo, Anna Rodó Pin, I. Blanco, Anna Herranz Blasco, L. M. Ferragut, L. Piccari, J. Barberà, D. R. Chiaradía

{"title":"Evolution of patients with Pulmonary Arterial Hypertension (PAH) six months after an exercise training program","authors":"Clara Martin Ontiyuelo, Anna Rodó Pin, I. Blanco, Anna Herranz Blasco, L. M. Ferragut, L. Piccari, J. Barberà, D. R. Chiaradía","doi":"10.1183/13993003.congress-2019.pa4753","DOIUrl":"https://doi.org/10.1183/13993003.congress-2019.pa4753","url":null,"abstract":"Introduction: In stable patients with Pulmonary Arterial Hypertension (PAH), exercise training (ET) in addition to appropriate pharmacological treatment is effective, safe and cost-effective. However, the long-term impact of this intervention remains unclear. For this, we evaluated exercise capacity, right ventricular response during exercise and daily physical activity (DPA) 6 months after the end of an ET program in these patients. Methods: A prospective analysis of 10 consecutive patients with PAH (idiopathic=3; VIH=3, connective tissue disease=3 and atrial septal defect=1) that successfully finished an ET program (8 weeks) was evaluated after 6 months. Incremental cardiopulmonary exercise testing (ICPET) with synchronic echocardiography and accelerometer validated for the assessment of daily DPA were used to evaluate the outcomes. Results: All patients showed training-induced increase on endurance time (mean change 287 seconds). Compared to values immediately after the completion of ET, 6 monthspeak VO2 and peak watts did not change significantly (51% vs 50% predicted, and 75% vs 67% predicted; respectively). In addition, pulmonary tricuspid valve regurgitation (TVR) and tricuspid annular plane systolic excursion (TAPSE) did not show significant differences during the follow-up at rest (4.16 vs 4.13 m/sec and 22.4 vs 22.7 cm;respectively) and at the end of exercise (3.9 vs 4.0 m/sec and 24 vs 22 cm). DPA was similar in two time points (after ET=6889 steps per day and 6 months=6753 steps per/day). Conclusions: In patients with PAH, exercise training maintains exercise capacity, right ventricular function and daily physical activity up to 6 months after the end of the program.","PeriodicalId":20724,"journal":{"name":"Pulmonary hypertension","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84553250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1